May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Combined Use of Anecortave-PDT for the Treatment of Retinal Angiomatous Proliferation Stage 2-3 in Age-Related Macular Degeneration
Author Affiliations & Notes
  • S. Marchi
    Ophthalmology, Sacco Hospital Milan, Milan, Italy
  • P. Ramolfo
    Ophthalmology, Sacco Hospital Milan, Milan, Italy
  • E. Mantovani
    Ophthalmology, Sacco Hospital Milan, Milan, Italy
  • E. Marziani
    Ophthalmology, Sacco Hospital Milan, Milan, Italy
  • G. Staurenghi
    Ophthalmology, Sacco Hospital Milan, Milan, Italy
  • Footnotes
    Commercial Relationships  S. Marchi, None; P. Ramolfo, None; E. Mantovani, None; E. Marziani, None; G. Staurenghi, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 548. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Marchi, P. Ramolfo, E. Mantovani, E. Marziani, G. Staurenghi; Combined Use of Anecortave-PDT for the Treatment of Retinal Angiomatous Proliferation Stage 2-3 in Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(13):548. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To report the results of retinal angiomatous proliferation (RAP) treatment using subtenon injection of Anecortave combined with PDT.

Methods: : This is a prospective review of consecutive patients with age-related macular degeneration who underwent treatment of RAP from June 1, 2006, through June 1, 2008. Inclusion criteria were: no previous treatment and diagnosis of RAP at stage 2-3 based on dynamic indocyanine green angiography (ICGA) and fluorescein angiography (FA). Patients received a subtenon injection of Anecortave followed by PDT after 15 days. Follow-up visits were scheduled every months with visual acuity (ETDRS charts), FA and ICGA. Decision for retreatment was based upon worsening of leakage on angiography and/or decreased visual acuity. Retreatment protocol included a PDT every three months. All patients underwent a repeated injection of Anecortave after six months.

Results: : Ten patients (10 eyes) with stage 2 RAP (6 eyes) and with stage 3 RAP (4 eyes) were identified. Ten patients were followed for at least six months and 4 patients for 12 months.During injection of Anecortave blooding and reflux occurred in 3 patients each.At six months, a functional improvement (> = 2 lines) was achieved in 3 Patients: 2 at stage 2 and 1 stage 3. A steady state was recorded in 5 patients (3 at stage 2 and 2 at stage 3) and decreased vision (<= 2 lines) occurred in 2 patients: 1 at stage 2 and 1 at stage 3.Anatomically, all the lesions remained perfused after treatment.Only 4 patients were seen after 12 months of follow-up, so the results are still preliminary.

Conclusions: : Six months results after combined treatment of Anecortave-PDT seem to be promising with 8 out of 10 patients showing a stable or improved functional outcome. We are waiting for results at 12 months of follow-up.

Keywords: age-related macular degeneration • corticosteroids • photodynamic therapy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×